Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-11 23:22 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Young Richard A | Director | BUY | $1.65 | 15,151 | $24,999 | 170,010 |
| 2025-09-12 02:43 | 2025-09-09 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.94 | 21,046 | $40,867 | 1,874,710 |
| 2025-09-12 04:45 | 2025-09-09 | CRMD | CorMedix Inc. | Zelnick Kaufman Beth | Officer | OPT+S | $13.41 | 50,000 | $670,265 | 180,418 |
| 2025-09-12 04:45 | 2025-09-09 | CRMD | CorMedix Inc. | Hurlburt Elizabeth | Officer | OPT+S | $13.18 | 53,997 | $711,815 | 176,990 |
| 2025-09-12 01:57 | 2025-09-09 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | SELL | $11.44 | 4,325 | $49,460 | 126 |
| 2025-09-11 23:59 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Polaris Management Co. VII, L.L.C. | 10% owner | BUY | $1.53 | 1,307,189 | $1,999,999 | 197,661 |
| 2025-09-12 04:01 | 2025-09-09 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $46.69 | 6,666 | $311,214 | 49,342 |
| 2025-09-11 23:16 | 2025-09-10 | BSPK | Bespoke Extracts, Inc. | FEINSOD MICHAEL | Director, Officer, 10% owner | BUY | $0.22 | 3,500 | $785 | 2,512,112 |
| 2025-09-11 23:05 | 2025-09-09 | ALNY | Alnylam Pharmaceuticals Inc. | Reitan Colleen F | Director | OPT+S | $467.60 | 18,000 | $8,416,730 | 775 |
| 2025-09-12 03:38 | 2025-09-10 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $72.45 | 2,200 | $159,390 | 0 |
| 2025-09-12 02:41 | 2025-09-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $397.97 | 8,000 | $3,183,777 | 130 |
| 2025-09-11 23:30 | 2025-09-09 | PTCT | PTC THERAPEUTICS, INC. | SOUTHWELL DAVID P | Director | OPT+S | $58.34 | 12,000 | $700,080 | 16,850 |
| 2025-09-12 03:56 | 2025-09-09 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.59 | 21,120 | $857,314 | 38,360 |
| 2025-09-12 02:32 | 2025-09-10 | SMMT | Summit Therapeutics Inc. | DUGGAN ROBERT W | Director, Officer, 10% owner | BUY | $17.69 | 338,394 | $5,984,769 | 556,093,090 |
| 2025-09-11 00:39 | 2025-09-09 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | OPT+S | $25.83 | 150,000 | $3,874,020 | 15,000 |
| 2025-09-10 23:15 | 2025-09-08 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | Officer | OPT+S | $38.33 | 5,000 | $191,650 | 171,928 |
| 2025-09-11 01:21 | 2025-09-08 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $17.54 | 10,129 | $177,628 | 891,440 |
| 2025-09-11 00:36 | 2025-09-09 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | Officer | BUY | $8.07 | 6,000 | $48,440 | 105,484 |
| 2025-09-11 02:48 | 2025-09-08 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | OPT+S | $44.17 | 12,500 | $552,136 | 167,124 |
| 2025-09-11 03:12 | 2025-09-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $20.24 | 6,667 | $134,957 | 283,308 |
| 2025-09-10 23:19 | 2025-09-08 | PRGO | PERRIGO Co plc | Lennox Abigail | Officer | BUY | $22.41 | 1,255 | $28,125 | 1,255 |
| 2025-09-11 00:50 | 2025-09-08 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $0.00 | 17,000 | $0 | 0 |
| 2025-09-10 23:02 | 2025-09-08 | APLS | Apellis Pharmaceuticals Inc. | Sullivan Timothy Eugene | Officer | OPT+S | $27.85 | 42,729 | $1,190,131 | 60,396 |
| 2025-09-11 00:00 | 2025-09-08 | CPRX | CATALYST PHARMACEUTICALS, INC. | Elsbernd Brian | Officer | OPT+S | $20.30 | 30,000 | $609,000 | 271,039 |
| 2025-09-11 00:19 | 2025-09-08 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $24.99 | 1,260 | $31,487 | 3,027,864 |
| 2025-09-10 22:09 | 2025-09-05 | CYCC | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% owner | SELL | $7.01 | 19,054 | $133,569 | 385,411 |
| 2025-09-10 23:31 | 2025-09-09 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $400.29 | 700 | $280,203 | 520 |
| 2025-09-10 23:31 | 2025-09-08 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $395.82 | 16,375 | $6,481,613 | 0 |
| 2025-09-10 23:30 | 2025-09-10 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $403.36 | 4,560 | $1,839,322 | 8,480 |
| 2025-09-10 23:31 | 2025-09-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $398.55 | 8,000 | $3,188,374 | 130 |
| 2025-09-10 23:13 | 2025-09-09 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $51.29 | 2,000 | $102,580 | 140,610 |
| 2025-09-10 01:30 | 2025-09-05 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $62.00 | 250 | $15,500 | 31,926 |
| 2025-09-09 23:40 | 2025-09-05 | PHAT | Phathom Pharmaceuticals, Inc. | Breedlove Robert Charles | Officer | SELL | $12.09 | 461 | $5,573 | 47,931 |
| 2025-09-09 23:02 | 2025-09-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | McAvoy David R. | Officer | BUY | $18.86 | 1,113 | $20,988 | 13,027 |
| 2025-09-09 23:15 | 2025-09-05 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $7.00 | 729,365 | $5,108,983 | 14,727,516 |
| 2025-09-10 01:37 | 2025-09-08 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | OPT+S | $19.11 | 871 | $16,645 | 149,025 |
| 2025-09-10 01:32 | 2025-09-08 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | Officer | OPT+S | $19.11 | 1,520 | $29,047 | 43,305 |
| 2025-09-10 00:31 | 2025-09-05 | ONC | BeOne Medicines Ltd. | Sanders Corazon (Corsee) D. | Director | OPT+S | $337.00 | 2,665 | $898,105 | 0 |
| 2025-09-10 00:53 | 2025-09-05 | RNA | Avidity Biosciences, Inc. | WILSON TROY EDWARD | Director | OPT+S | $50.00 | 29,500 | $1,475,000 | 54,425 |
| 2025-09-09 22:47 | 2025-09-05 | PRGO | PERRIGO Co plc | Atkinson Charles | Officer | BUY | $23.20 | 1,000 | $23,200 | 1,000 |
| 2025-09-10 03:11 | 2025-09-08 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Director | BUY | $127.28 | 1,575 | $200,466 | 48,212 |
| 2025-09-09 23:31 | 2025-09-05 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $13.41 | 2,640 | $35,402 | 199,539 |
| 2025-09-09 23:26 | 2025-09-05 | AGIO | Agios Pharmaceuticals Inc. | Washburn Theodore James Jr. | Officer | SELL | $36.87 | 8,546 | $315,091 | 868 |
| 2025-09-09 23:28 | 2025-09-08 | KURA | Kura Oncology, Inc. | WILSON TROY EDWARD | Director, Officer | BUY | $8.20 | 50,000 | $410,145 | 100,968 |
| 2025-09-09 23:21 | 2025-09-08 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $46.29 | 6,322 | $292,645 | 1,111,983 |
| 2025-09-10 02:02 | 2025-09-08 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $15.84 | 7,294 | $115,537 | 395,189 |
| 2025-09-10 04:07 | 2025-09-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | SELL | $445.63 | 7,279 | $3,243,741 | 102,474 |
| 2025-09-10 01:30 | 2025-09-05 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | SELL | $59.60 | 6,000 | $357,581 | 82,679 |
| 2025-09-10 00:00 | 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | OPT+S | $56.92 | 39,850 | $2,268,374 | 72,912 |
| 2025-09-08 23:37 | 2025-09-08 | BHC | Bausch Health Companies Inc. | Carson Seana | Officer | SELL | $7.31 | 13,370 | $97,735 | 499,585 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.